Primary carcinoid tumors of the lung: A role for radiotherapy

Gregory M.M. Videtic, Heath B. MacKley

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma. The rarity of carcinoids has made the role of radiation therapy in their management controversial. This review considers the results of published studies to generate treatment recommendations and identify areas forfuture research. Surgery rthe standard of care for medically operable disease. Histology plays the most important role in determining the role of adjuvant radiation. Resected typical carcinoids likely do not require adjuvant therapy irrespective of nodal status. Resected atypical carcinoids and large-cell neuroendocrine carcinomas have a significant risk of local failure, for which adjuvant radiation likely improves local control. Definitive radiation is warranted in unresectable disease. Palliative radiation for symptomatic lesions has demonstrated efficacy for all histologies. Collaborative group trials are warranted.

Original languageEnglish (US)
Pages (from-to)1537-1543
Number of pages7
JournalONCOLOGY
Volume20
Issue number12
StatePublished - Nov 1 2006

Fingerprint

Carcinoid Tumor
Radiotherapy
Radiation
Lung
Histology
Neuroendocrine Carcinoma
Large Cell Carcinoma
Small Cell Lung Carcinoma
Standard of Care
Lung Neoplasms
Therapeutics
Research
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Videtic, Gregory M.M. ; MacKley, Heath B. / Primary carcinoid tumors of the lung : A role for radiotherapy. In: ONCOLOGY. 2006 ; Vol. 20, No. 12. pp. 1537-1543.
@article{5e68ebd1a39f4cb49a631bb3706c89c4,
title = "Primary carcinoid tumors of the lung: A role for radiotherapy",
abstract = "Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma. The rarity of carcinoids has made the role of radiation therapy in their management controversial. This review considers the results of published studies to generate treatment recommendations and identify areas forfuture research. Surgery rthe standard of care for medically operable disease. Histology plays the most important role in determining the role of adjuvant radiation. Resected typical carcinoids likely do not require adjuvant therapy irrespective of nodal status. Resected atypical carcinoids and large-cell neuroendocrine carcinomas have a significant risk of local failure, for which adjuvant radiation likely improves local control. Definitive radiation is warranted in unresectable disease. Palliative radiation for symptomatic lesions has demonstrated efficacy for all histologies. Collaborative group trials are warranted.",
author = "Videtic, {Gregory M.M.} and MacKley, {Heath B.}",
year = "2006",
month = "11",
day = "1",
language = "English (US)",
volume = "20",
pages = "1537--1543",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "12",

}

Videtic, GMM & MacKley, HB 2006, 'Primary carcinoid tumors of the lung: A role for radiotherapy', ONCOLOGY, vol. 20, no. 12, pp. 1537-1543.

Primary carcinoid tumors of the lung : A role for radiotherapy. / Videtic, Gregory M.M.; MacKley, Heath B.

In: ONCOLOGY, Vol. 20, No. 12, 01.11.2006, p. 1537-1543.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Primary carcinoid tumors of the lung

T2 - A role for radiotherapy

AU - Videtic, Gregory M.M.

AU - MacKley, Heath B.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma. The rarity of carcinoids has made the role of radiation therapy in their management controversial. This review considers the results of published studies to generate treatment recommendations and identify areas forfuture research. Surgery rthe standard of care for medically operable disease. Histology plays the most important role in determining the role of adjuvant radiation. Resected typical carcinoids likely do not require adjuvant therapy irrespective of nodal status. Resected atypical carcinoids and large-cell neuroendocrine carcinomas have a significant risk of local failure, for which adjuvant radiation likely improves local control. Definitive radiation is warranted in unresectable disease. Palliative radiation for symptomatic lesions has demonstrated efficacy for all histologies. Collaborative group trials are warranted.

AB - Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma. The rarity of carcinoids has made the role of radiation therapy in their management controversial. This review considers the results of published studies to generate treatment recommendations and identify areas forfuture research. Surgery rthe standard of care for medically operable disease. Histology plays the most important role in determining the role of adjuvant radiation. Resected typical carcinoids likely do not require adjuvant therapy irrespective of nodal status. Resected atypical carcinoids and large-cell neuroendocrine carcinomas have a significant risk of local failure, for which adjuvant radiation likely improves local control. Definitive radiation is warranted in unresectable disease. Palliative radiation for symptomatic lesions has demonstrated efficacy for all histologies. Collaborative group trials are warranted.

UR - http://www.scopus.com/inward/record.url?scp=39049192906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049192906&partnerID=8YFLogxK

M3 - Review article

C2 - 17153907

AN - SCOPUS:39049192906

VL - 20

SP - 1537

EP - 1543

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 12

ER -